Department of Pharmacy, Kanazawa University Hospital, 13-1 Takara-machi, Kanazawa 920-8641, Japan.
Gastroenterol Res Pract. 2012;2012:963403. doi: 10.1155/2012/963403. Epub 2012 May 16.
Treatment of cancers in the abdominal cavity, such as peritoneal dissemination, is difficult, but in principle intraperitoneal administration of anticancer drugs is expected to be preferable to systemic administration. Taxane anticancer drugs are used to treat gastric cancer patients with peritoneal dissemination. They are administered as micellar preparations, Taxol and Taxotere, which consist of paclitaxel in Cremophor EL (crEL) and docetaxel in Polysorbate-80 (PS-80), respectively. In this paper we review the disposition kinetics of taxane anticancer drugs after intraperitoneal administration in peritoneal dissemination patients and animal models and also discuss the effect of the surfactant vehicle on the behavior of taxanes.
腹腔内癌症的治疗,如腹膜转移,较为困难,但原则上腹腔内给予抗癌药物可能优于全身给予。紫杉醇类抗癌药物用于治疗有腹膜转移的胃癌患者。它们以胶束制剂紫杉醇(Taxol)和多西紫杉醇(Taxotere)的形式给予,分别由聚氧乙烯蓖麻油(crEL)中的紫杉醇和聚山梨醇酯 80(PS-80)中的多西紫杉醇组成。本文综述了在腹膜转移患者和动物模型中腹腔内给予紫杉醇类抗癌药物后的处置动力学,并讨论了表面活性剂载体对紫杉烷类药物行为的影响。